Nektar Therapeutics (NKTR)

Market Cap	1.41B +30.7%
Revenue (ttm)	54.59M -27.2%
Net Income	-157.13M
EPS	-6.47
Shares Out	34.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,174,737
Open	40.38
Previous Close	40.80
Day's Range	40.33 - 42.38
52-Week Range	33.40 - 109.00
Beta	1.27
Analysts	Buy
Price Target	141.40 (+243.45%)
Est. Earnings	Nov 5, 2026

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has col...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 3, 1994
• Employees: 63
• Stock Exchange: Nasdaq
• Ticker Symbol: NKTR
• Website: https://www.nektar.com

Financial Performance

In 2025, Nektar Therapeutics's revenue was $55.23 million, a decrease of -43.89% compared to the previous year's $98.43 million. Losses were -$164.08 million, 37.9% more than in 2024.

Analyst Summary

According to 13 analysts, the average rating for NKTR stock is "Buy." The 12-month stock price target is $141.4, which is an increase of 243.45% from the latest price.

Price Target

$141.4

(243.45% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error